Drug intelligence / Profile preview

en-3270

Development stage: Unknown
Lead developer: Durect
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Transdermal

Overview

EN-3270 is a transdermal agent developed for opioid-experienced patients with non-malignant moderate to severe chronic pain. It was designed as a sustained-release formulation to provide continuous pain relief in patients already stabilized on opioid therapy. The drug leverages transdermal delivery technology to maintain consistent plasma levels and improve patient compliance. Clinical trials focused on its safety and titration schedules in this population. The developer, Durect, specializes in innovative drug delivery systems for chronic conditions[1][2][3].

Brand names: TRANSDUR-Sufentanil
Other names: sufentanil transdermal systemsufentanil patch

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on en-3270.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on en-3270.

Explore the full profile